secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2026-08-13T12:35:22+00:00
Accession:  0001140361-26-032650
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech refocuses on PDS0301, discontinues PDS0101 Phase 3 trial; Q2 net loss $9.8M
--------------------------------------------------------------------------------

- Q2 2026 net loss $9.8M ($0.18/share) vs $9.4M ($0.21) year-ago; cash $5.6M at June 30.
- Strategic refocus: PDS0301 (IL-12 immunocytokine) becomes lead program; PDS0101 VERSATILE-003 Phase 3 trial discontinued.
- Positive mCRC data: ORR 77.8% (7/9) with PDS0301 vs 35% (7/20) without; 24-month survival ~80% vs ~35%.
- Company to pursue partnerships for PDS0101 development; R&D expenses down to $3.3M from $4.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036126032650/0001140361-26-032650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036126032650/ef20080122_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-032650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer